Daniel H. Schneiderman - 01 May 2026 Form 4 Insider Report for Pasithea Therapeutics Corp. (KTTA)

Reporting relationship: Chief Financial Officer
Issuer ticker: KTTA
Reported as of: 01 May 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 05 May 2026, 16:41:34 UTC
Prior SEC filing: 01 Dec 2025
Source filing: View source filing
Reporting owner signature: /s/ Daniel Schneiderman

Key filing fact

Daniel H. Schneiderman filed Form 4 for Pasithea Therapeutics Corp. (KTTA) on 05 May 2026.

Key facts

This page summarizes Daniel H. Schneiderman's Form 4 filing for Pasithea Therapeutics Corp. (KTTA).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 05 May 2026, 16:41.

Change

Previous filing in this sequence was filed on 01 Dec 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001565536 Primary reporting owner

Schneiderman Daniel H

Relationship: Chief Financial Officer
Address: 1111 LINCOLN ROAD, SUITE 500, MIAMI BEACH
Signature: /s/ Daniel Schneiderman
Signature date: 05 May 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

KTTA transaction Derivative

Stock Option (right to buy)

Award

Transaction value
Shares: +1,129,323
Change %
Price: $0.000000^*
Shares after: 1,129,323
Date: 01 May 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 1,129,323
Exercise price: $0.8410
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The option (the "Option") award was made in accordance with the terms of the Issuer's 2023 Stock Incentive Plan, as amended (the "Plan"). The shares of the Issuer's common stock, par value $0.0001 per share, underlying the Option will vest at the rate of 33% upon the one-year anniversary of the date of grant and the remaining shares will vest in equal quarterly installments thereafter for the next two years; provided, that the Reporting Person remains in continuous service to the Issuer through such vesting dates; provided further, that the shares underlying the Option will fully vest upon a Change in Control (as defined in the Plan). Additionally, all vested and exercisable shares underlying the Option held by the grantee may be exercised by the grantee for a period of up until three (3) years following termination of Continuous Service (as defined in the Plan), other than a termination for Cause (as defined in the Plan).